)
Visual24 Oct 2025
The rise of Alphabet
Fulgent Genetics (FLGT) investor relations material
Fulgent Genetics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary1 Aug, 2025
Executive summary
Core revenue reached $81.7M–$82M, up 15–16% year-over-year, with total revenue at $81.8M for Q2 2025, driven by growth in laboratory services, precision diagnostics, and recent acquisitions.
Net loss was $19M, impacted by a $9.9M non-cash impairment charge; non-GAAP income was $2.1M ($0.07 per share).
Gross margin improved to 42–42.1% (GAAP) and 44.1–44.2% (non-GAAP), with gross profit up 30% year-over-year.
Expanded managed care agreements, launched new genome sequencing services, and completed acquisitions of Inform Diagnostics, CSI Labs, and ANP/AMP Technologies.
Ended Q2 with $777.5M–$778M in cash, cash equivalents, and marketable securities.
Financial highlights
Q2 2025 core revenue: $81.7M–$82M, up 16% year-over-year; total revenue: $81.8M.
GAAP gross margin: 42–42.1%; non-GAAP gross margin: 44.1–44.2%.
Operating loss: $19.7M (GAAP); non-GAAP operating loss: $7.7M; adjusted EBITDA loss: $3M.
Net loss per share: ($0.62) GAAP; non-GAAP EPS: $0.07.
Share repurchases totaled 130,000–200,000 shares for $2.2M–$3M in Q2; $139.6M remains under the program.
Outlook and guidance
Raised 2025 core revenue guidance to $320M, representing 14% year-over-year growth.
Full-year non-GAAP gross margin expected to slightly exceed 40%; non-GAAP operating margin to improve to -13%.
Non-GAAP EPS guidance improved to a loss of $0.35 per share; GAAP EPS guidance at a loss of $2.10 per share.
Year-end 2025 cash and investments projected at ~$770M, with sufficient liquidity for ongoing investments.
R&D expenses expected to rise as clinical trials progress; no material future COVID-19 testing revenue expected.
Why is cash guidance lower than current cash?
How much has been spent on share repurchases?
Explain the progress in clinical trials.
Assess impact of Paclitaxel inclusion on FID-007.
How will AAP guidelines affect market penetration?
Detail the organic gross margin, excluding adjustments.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Fulgent Genetics earnings date
Q3 20257 Nov, 2025
Next Fulgent Genetics earnings date
Q3 20257 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Fulgent Genetics, Inc. provides clinical genetic testing services in the United States and internationally. It offers genetic testing services for various types of heredity conditions, such as intellectual disability and movement disorders; infectious diseases, including sexually transmitted infections; pharmacogenetic tests to help individuals determine drug sensitivities; oncology testing services focused on inherited cancer predisposition; prenatal genetic testing for genetic abnormalities; and pediatric and adult behavioral tests for attention deficit hyperactivity disorders. The company also provides COVID-19 testing kits to physicians. In addition, it offers development of customized multi-gene panels for clinical trial recruitment, which are designed for specific panels of genes associated with various genotypes or phenotypes; and PathFinderTG tool that evaluates the likelihood that a patient's symptoms could be caused by an underlying genetic condition. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage